1 |
He YF, Ji CS, Hu B, et al (2013). A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol, 19, 5910.
DOI
|
2 |
Jiang J, Liang X, Zhou X, et al (2012). ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep, 39, 6933-42.
DOI
|
3 |
Kaya V, Yildirim M, Demirpence O, et al (2013). Prognostic significance of basic laboratory methods in non- small-celllung cancer. Asian Pac J Cancer Prev, 14, 5473-6.
과학기술학회마을
DOI
ScienceOn
|
4 |
Lee JJ, Maeng CH, Baek SK, et al (2010). The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 70, 205-10.
DOI
|
5 |
Mutlu H, Buyukcelik A, Aksahin A, et al (2013). Does sunlight exposure improve survival in patients with non-small cell lung cancer? Asian Pac J Cancer Prev, 14, 6301-4.
과학기술학회마을
DOI
|
6 |
Natukula K, Jamil K, Pingali UR, et al (2013). The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians. Asian Pac J Cancer Prev, 14, 5275-9.
과학기술학회마을
DOI
ScienceOn
|
7 |
Oven Ustaalioglu BB, Unal OU, Turan N, et al (2013). Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences. Asian Pac J Cancer Prev, 14, 6287-92.
과학기술학회마을
DOI
ScienceOn
|
8 |
Cai Y, Wang JY, Liu H (2013). Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure. Asian Pac J Cancer Prev, 14, 5699-703.
과학기술학회마을
DOI
ScienceOn
|
9 |
Dalla-Torre CA, de Toledo SRC, Yoshimoto M, et al (2007). Expression of major vault protein gene in osteosarcoma patients. J Orthop Res, 25, 958-63.
DOI
|
10 |
Rossi D, Graziano F, Catalano V, et al (2001). A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study. Anticancer Res, 22, 3087-92.
|
11 |
Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
DOI
ScienceOn
|
12 |
Sugiyama T, Hirose T, Nakashima M, et al (2011). Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer. Oncology, 81, 273-80.
DOI
ScienceOn
|
13 |
Unal D, Eroglu C, Kurtul N, et al (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev, 14, 5237-42.
과학기술학회마을
DOI
ScienceOn
|
14 |
Aydiner A, Ciftci R, Karabulut S, et al (2013). Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer? Asian Pac J Cancer Prev, 14, 6109-14.
과학기술학회마을
DOI
ScienceOn
|
15 |
Bepler G, Kusmartseva I, Sharma S, et al (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol, 24, 4731-7.
DOI
ScienceOn
|
16 |
Ueno H, Ioka T, Ikeda M, et al (2013). Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol, 31, 1640-8.
DOI
|
17 |
Valle J, Wasan H, Palmer D H, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81.
DOI
ScienceOn
|
18 |
Wang X, Zhao J, Yang L, et al (2010). Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol, 27, 484-90.
DOI
ScienceOn
|
19 |
Wang JY, Cai Y (2013). Clinical observation and prognostic analysis of pemetrexed plus platinum as first-line treatment in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 6267-71.
과학기술학회마을
DOI
ScienceOn
|
20 |
Wang M, Gu J, Wang HX, et al (2012). Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. Asian Pac J Cancer Prev, 13, 4153-6.
과학기술학회마을
DOI
ScienceOn
|
21 |
Teramoto K, Asada Y, Ozaki Y, et al (2012). A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer. Cancer Chemother Pharmacol, 70, 531-7.
DOI
ScienceOn
|